30 min listen
Non–small cell lung cancer: How to choose the best therapy and reviewing the first virtual ASCO
FromBlood & Cancer
Non–small cell lung cancer: How to choose the best therapy and reviewing the first virtual ASCO
FromBlood & Cancer
ratings:
Length:
36 minutes
Released:
Jun 4, 2020
Format:
Podcast episode
Description
Jack West, MD, joins the podcast to discuss how he chooses first-line treatment in new patients with non–small cell lung cancer (NSCLC). Dr. West is an associate clinical professor in medical oncology at City of Hope Comprehensive Cancer Center in Duarte, Calif., and a thought leader in thoracic oncology. Dr. West also explores how the COVID-19 pandemic influences treatment approaches, the usefulness of liquid biopsy, and how he weighs the potentially higher risk for COVID-19 complications from checkpoint inhibitors. Check out Dr. West’s last two appearances on the podcast: https://www.mdedge.com/podcasts/blood-cancer/immunotherapy-lung-cancer-dr-jack-west-part-1 https://www.mdedge.com/podcasts/blood-cancer/immunotherapy-lung-cancer-dr-jack-west-part-2 Disclosures: Dr. Henry reported having no financial disclosures relevant to this episode. Dr. West has a full list of his financial disclosures here. * * * For more MDedge Podcasts, go to mdedge.com/podcasts Email the show: podcasts@mdedge.com Interact with us on Twitter: @MDedgehemonc David Henry on Twitter: @davidhenrymd
Released:
Jun 4, 2020
Format:
Podcast episode
Titles in the series (100)
Common bleeding and coagulation issues: There’s an art to taking a thorough bleeding history. In this episode, , director of the Hemophilia and Thrombosis Center at the University of Pennsylvania, Philadelphia, shares the most important questions to ask and the challenges in assessing... by Blood & Cancer